Rising Unmet Need in Multiple Myeloma Management After First-Line Treatment With DRd: Expected Epidemiological Evolution in Italy
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Mario Boccadoro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Antineoplastic Combined Chemotherapy Protocols, Lenalidomide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Menarini Group.
Abstract (Originalsprache)
BACKGROUND: In Italy, newly diagnosed Multiple Myeloma (MM) patients not eligible for autologous stem cell transplantation (ASCT) recently benefitted from a therapeutic advancement with the reimbursement of the combination daratumumab plus lenalidomide and dexamethasone (DRd) as frontline treatment. The introduction of this combination in first-line (1 L) is expected to generate an unmet medical need in second-line (2 L), since there are only three 2 L therapeutic options recommended by ESMO guidelines and reimbursed in Italy for lenalidomide-refractory patients post-DRd. MATERIALS AND METHODS: An epidemiological model was developed to estimate the number of Italian patients progressing to 2 L therapy after receiving DRd in 1 L over a 3-year time horizon (2025-2027) following a three-step procedure: (1) identification of the cohort of patients starting 1 L therapy with DRd in each quarterly cycle; (2) estimation of the number of patients experiencing disease progression or death in each cycle, through the long-term extrapolation of the progression-free survival (PFS) curve from the DRd clinical trial; (3) calculation of the number of patients eligible for 2 L therapy in each cycle. RESULTS: The cumulative number of ASCT-ineligible MM patients in 2 L after receiving DRd in 1 L in Italy amounts to 1743 between 2025 and 2027. CONCLUSION: This study highlights the increasingly urgent unmet medical need developing in the 2 L setting following DRd in Italy, due to the large number of patients relapsing after 1 L therapy with DRd, for whom available treatment options are limited as they might not be eligible for DRd, thus intensifying their disease burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
- IQVIA Solutions Italy S.r.l., Milan, Italy. Electronic address: riccardo.mercati@iqvia.com.
- IQVIA Solutions Italy S.r.l., Milan, Italy.
- Biostatistics & Outcome Research, Statinfo, Milan, Italy; Bicocca Applied Statistics Center (B-ASC), Università degli Studi di Milano-Bicocca, Milan, Italy.
Förderung
- Menarini Group
Zitieren
APA
Boccadoro, M., Mercati, R., Vassallo, C., Canali, B., Fiorentino, F., & Galeone, C. (2025). Rising Unmet Need in Multiple Myeloma Management After First-Line Treatment With DRd: Expected Epidemiological Evolution in Italy. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.07.001
Vancouver
Boccadoro M, Mercati R, Vassallo C, Canali B, Fiorentino F, Galeone C. Rising Unmet Need in Multiple Myeloma Management After First-Line Treatment With DRd: Expected Epidemiological Evolution in Italy. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.07.001
BibTeX
@article{Boccadoro2025,
author = {Boccadoro, Mario and Mercati, Riccardo and Vassallo, Chiara and Canali, Beatrice and Fiorentino, Francesca and Galeone, Carlotta},
title = {Rising Unmet Need in Multiple Myeloma Management After First-Line Treatment With DRd: Expected Epidemiological Evolution in Italy},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.07.001}
}
EUVIMED